Sanofi is replacing Paul Hudson as CEO, amid questions about which medicines will drive the company's growth in the future.

Sanofi shares fell after the company said Belen Garijo, the chief executive of Germany’s Merck KGaA, would succeed Paul ...

The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent ...

Sanofi said Belen Garijo, the chief executive of Merck KGaA, would succeed Paul Hudson as CEO after the board of directors decided not to renew Hudson's mandate.

Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.

Sanofi (FR:SAN) has been in the ranks of Europe’s underperforming pharmaceutical companies for the past few years, as the ...

Sanofi abruptly replaced Chief Executive Officer Paul Hudson after a massive research spending boost failed to deliver rapid ...

Sanofi’s Board of Directors announced Belén Garijo as the company’s next CEO following the move to not renew the tenure of ...

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...

PHARMAP 2026 addresses this transformation with a specialised session on patient-friendly design and its role in modern medicine. The event is scheduled for 20-21 April in Amsterdam. Trust and ...

At Sanofi, AI has shifted from experimentation to becoming a vital part of our infrastructure.